Trial Profile
A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms JIGSAW118
- Sponsors Roche
- 28 Jan 2021 Results of two clinical trials in children with systemic juvenile idiopathic arthritis (n=51; NCT01904292) and polyarticular juvenile idiopathic arthritis (n=52; NCT01904279) conducted to identify optimal dosing regimens of subcutaneous tocilizumab published in the Rheumatology.
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 21 Sep 2018 According to Roche media release, based on ths data from this study the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the subcutaneous (SC) formulation of RoActemra (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients one year of age and older.